Compare Amgen, Inc. (AMGN) vs Chevron Corp (CVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Chevron Corp — how do they compare? Amgen, Inc. trades at $356.92 (market cap $196.12B), while Chevron Corp trades at $180.66 (market cap $351.32B). The key difference: Chevron Corp is the larger of the two by market cap, and Chevron Corp pays the higher dividend (4.04%). Which is the better fit depends on your goals.
| AMGN | CVX | |
|---|---|---|
Market Cap | $196.12B | $351.32B |
Sector | Health | Energy |
52-Week High | $388.16 | $211.14 |
52-Week Low | $271.18 | $146.72 |
Enterprise Value | $241.41B | $391.42B |
Dividend Yield | 2.77% | 4.04% |
Volume | — | 9,807,834 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CVX trades at $176.4, up 1.35% on the day, with a neutral technical signal and recent earnings beats. The stock shows strong analyst support (62% buy ratings) and a consensus price target of $207.56, implying 17.7% upside. Revenue declined to $184.43B in 2025, but operational cash flow remains robust at $33.94B. Recent news highlights geopolitical risks and Chevron's $13.8B investment in Argentina's Vaca Muerta shale project.
CVX offers value with a reasonable P/E of 30.73 and dividend yield, but faces headwinds from falling profit margins and oil price volatility. The stock's upside hinges on production growth and stable energy prices, while risks include geopolitical tensions and debt increases. Analyst optimism suggests potential gains if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →
